A rocky road to redemption for Dilip Shanghvi’s Sun Pharma3 min read 05 Dec 2018, 07:39 AM IST
Sun Pharma's management appears keen to resolve investor concerns and unwind transactions or structures they disapprove of, but there remain unanswered questions
Sun Pharmaceutical Industries Ltd tried its hand at limiting the damage from a scathing note by a brokerage firm and a whistleblower complaint to the Securities and Exchange of India (Sebi). The company issued a written statement clarifying its position, followed by a conference call with analysts and investors. But none of these seem to have helped. Leave alone a recovery, Sun Pharma shares fell another 2.7% on Tuesday, taking the drop in the past seven trading sessions to more than 15%.
Select your Category